Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics.

Alvarado A, Martinez-Ponce J, Ubysz O, Costa A, Ataya L, Brancheau D

JACC. Case reports25 Sept 2026

PMID42788915 (opens in a new tab)DOI10.1016/j.jaccas.2026.110528 (opens in a new tab)PepBankPUB-42788915
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an 82-year-old man with heart failure, starting semaglutide was followed by a 20-pound weight loss.

    In plain wordsIn one older man with heart failure, starting semaglutide was followed by a 20-pound weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss after semaglutide initiation
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    20 pounds
    case patient

    Source sentences

    Summary
    Initiation of semaglutide led to 20-pound weight loss, improved symptoms, and reduced mean pulmonary artery pressures (10 mm Hg).
    1 context sentence
    Summary · context
    An 82-year-old man with HF (left ventricular ejection fraction: 40%-45%; NYHA functional class III) had recurrent decompensation despite diuretic agents.
  2. 02HumanCase report or seriesEfficacy outcome

    In an 82-year-old man with heart failure and a CardioMEMS sensor, starting semaglutide was followed by a 10 mm Hg reduction in mean pulmonary artery pressure.

    In plain wordsIn one older man with heart failure, mean lung artery pressure fell by 10 mm Hg after he started semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean pulmonary artery pressure
    Study

    n = 1

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean pulmonary artery pressure reduction
    10 mm Hg
    case patient

    Source sentences

    Summary
    Initiation of semaglutide led to 20-pound weight loss, improved symptoms, and reduced mean pulmonary artery pressures (10 mm Hg).
    1 context sentence
    Summary · context
    An 82-year-old man with HF (left ventricular ejection fraction: 40%-45%; NYHA functional class III) had recurrent decompensation despite diuretic agents.
  3. 03HumanCase report or seriesEfficacy outcome

    In an 82-year-old man with heart failure, symptoms improved after semaglutide was started.

    In plain wordsIn one older man with heart failure, symptoms got better after he started semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeart failure symptoms
    Study

    n = 1

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Initiation of semaglutide led to 20-pound weight loss, improved symptoms, and reduced mean pulmonary artery pressures (10 mm Hg).
    1 context sentence
    Summary · context
    An 82-year-old man with HF (left ventricular ejection fraction: 40%-45%; NYHA functional class III) had recurrent decompensation despite diuretic agents.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.